Neurocrine Biosciences’ NBI-921352 Study Update: Implications and Insights

Neurocrine Biosciences ((NBIX)) announced an update on their ongoing clinical study.

Neurocrine Biosciences recently updated its clinical study on NBI-921352, aimed at evaluating its efficacy, safety, and pharmacokinetics as an adjunctive therapy for seizures in patients with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE). This Phase 2 study, officially titled ‘A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE),’ holds significant potential for addressing this rare and severe epilepsy disorder.

The intervention being tested is NBI-921352, an experimental drug administered orally, designed to reduce seizure frequency and severity in SCN8A-DEE patients. The study also includes a placebo group for comparison.

The study follows a randomized, parallel assignment model with triple masking (participant, care provider, investigator) to ensure unbiased results. Its primary purpose is treatment-focused, aiming to provide a new therapeutic option for this challenging condition.

The study began on January 31, 2022, but was terminated as of the last update on July 14, 2025. These dates are crucial for understanding the study’s timeline and the progress made before its termination.

The termination of this study could impact Neurocrine Biosciences’ stock performance and investor sentiment, as it may alter expectations for the company’s pipeline and future revenue. Investors should also consider the broader competitive landscape, where other companies are developing treatments for similar conditions.

While the study has been terminated, further details are available on the ClinicalTrials portal for those seeking more information.